Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals

American Heart Journal

Volumn 131, Issue 5, 1996, Pages 872-878

  Phillips, Bradley G ^a   Yim, Josephine M ^b   Brown Jr , Edward J ^c   Bittar, Neville ^d   Hoon, Timothy J ^d   Celestin, Catherine ^e   Vlasses, Peter H ^b   Bauman, Jerry L ^f  

^a UNIVERSITY OF IOWA   (United States)

^b University Hospital Consortium   (United States)

^c Cardiology Division   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANISTREPLASE; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; GEMFIBROZIL; GLYCERYL TRINITRATE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MAGNESIUM; METOPROLOL; NICOTINIC ACID; NIFEDIPINE; NITRATE; PROBUCOL; PROPRANOLOL; RESIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VERAPAMIL; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRADYCARDIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; FEMALE; GENDER; HEART BLOCK; HUMAN; HYPOTENSION; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 4 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURVIVAL RATE; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0029960011     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90167-2     Document Type: Article

References (41)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
2. GISSI-2 (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico). GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
3. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
4. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;2:57-66.
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
6. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-70.
7. Yim JM, Brown EJ, Bauman JL, Bittar N, Celestin C, Hoon TJ, Phillips BG, Vlasses PH. Angiotensin-converting enzyme inhibitor use in survivors of acute myocardial infarction. Am J Cardiol 1995;75:1184-6.
8. Pashos CL, Normand SLT, Garfinkle JB, Newhouse JP, Epstein AM, McNeil BJ. Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. J Am Coll Cardiol 1994;23:1023-30.
9. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, Rubison RM, Tiefenbrunn AJ, Weaver WD, for the participants in the National Registry of Myocardial Infarction. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation 1994; 90:2103-14.
10. Althouse R, Maynard C, Cerqueira MD, Olsufka M, Ritchie JL, Kennedy JW. The Western Washington Myocardial Infarction Registry and Emergency Department Tissue Plasminogen Activator Treatment Trial. Am J Cardiol 1990;66:1298-303.
11. Gore JM, Dalen JE. Cardiovascular disease. JAMA 1991;265:3105-7.
12. Muller DWM, Topol EJ. Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Intern Med 1990;113:949-60.
13. Grines CL, DeMaria AN. Optimal utilization of thrombolytic therapy for acute myocardial infarction: concept and controversies. J Am Coll Cardiol 1990;16:223-31.
14. Ferguson JJ. Meeting highlights. Circulation 1994;89:545-7.
15. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL, Clapp-Channing N, Knight JD, Harrell FE, Simes J, Topol EJ. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332:1418-24.
16. Krumholz HM, Pasternak RC, Weinstein MC, Friesinger GC, Ridker PM, Tosteson ANA, Goldman L. Cost effectiveness of thrombolytic therapy in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992;327:7-13.
17. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). Am J Cardiol 1985;56:1G-57G.
18. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989;320:618-27.
19. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
20. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol on patients with acute myocardial infarction. JAMA 1982;247:1707-14.
21. American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. Guidelines for the early management of patients with acute myocardial infarction. J Am Coll Cardiol 1990;16:249-92.
22. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92.
23. The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J 1984;5:516-28.
24. Muller JE, Morrison J, Stone PH, Rude RE, Rosner B, Roberts R, Pearle DL, Turi ZG, Schneider JF, Serfas DH, Tate C, Scheiner E, Sobel BE, Hennekens CH, Braunwald E. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation 1984;69:740-7.
25. Sirnes PA, Overskeid K, Pedersen TR, Bathen J, Drivenes A, Froland GS, Kjekshus JK, Landmark K, Rokseth R, Sirnes KE, Sundoy A, Torjussen BR, Westlund KM, Wik BA. Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: the Norwegian Nifedipine Multicenter Trial. Circulation 1984;70:638-44.
26. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatment following myocardial infarction. JAMA 1988;260:2088-93.
27. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992;327:248-54.
28. Ayanian JZ, Hauptman PJ, Guadagnoli E, Antman EM, Pashos CL, McNeil BJ. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med 1994;331:1136-42.
29. Roberts SA, Diaz C, Nolan PE, Salerno DM, Stapczynski JS, Zbrozek AS, Ritz EG, Bauman JL, Vlasses PH. Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am J Cardiol 1993;72:567-73.
30. Rasmussen HS, McNair P, Norregard P, Backer V, Lindeneg O, Balslov S. Intravenous magnesium in acute myocardial infarction. Lancet 1986;1:234-6.
31. Rasmussen HS, Suenson M, McNair P, Norregard P, Balslov S. Magnesium infusion reduces the incidence of arrhythmias in acute myocardial infarction: a double-blind placebo-controlled study. Clin Cardiol 1987;10:351-6.
32. Rasmussen HS, Gronbaek M, Cintin C, Balslov S, Norregard P, McNair P. One-year death rate in 270 patients with suspected acute myocardial infarction, initially treated with intravenous magnesium or placebo. Clin Cardiol 1988;11:377-81.
33. Abraham AS, Rosenmann D, Kramer M, Balkin J, Zion MM, Farbstien H, Eylath U. Magnesium in the prevention of lethal arrhythmias in acute myocardial infarction. Arch Intern Med 1987;147:753-5.
34. Shechter M, Hod H, Marks N, Behar S, Kaplinsky E, Rabinowitz B. Beneficial effect of magnesium sulfate in acute myocardial infarction. Am J Cardiol 1990;66:271-4.
35. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992;339:1553-8.
36. Teo KK, Yusuf S, Collins R, Held PH, Peto R. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomized trials. BMJ 1991;303:1499-503.
37. ISIS-4 Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
38. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223: 405-18.
39. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
40. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
41. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;23:3015-23.